Sumant Kulkarni

Michael Okunewitch

Rudy Li

Brian Abrahams

Charles Duncan

Marc Goodman

Christopher Chen

Elias Georgas

Gavin Clark-Gartner

Jay Olson

Joel Beatty

Luis Santos

Patrick Trucchio

Pete Stavropoulos

François Brisebois

James Nevin

Jason McCarthy

Madhumita Yennawar

- Mind Medicine (MindMed), Inc. reported estimated preliminary cash, cash equivalents, and investments of approximately **$209.1 million** as of **September 30, 2025**.  **[1813814_0001104659-25-103726_tm2529652d1_8k.htm:1]** **[1813814_0001104659-25-103726_tm2529652d1_ex99-1.htm:5]** 
- The company's cash runway is expected to extend into **2027**.  **[1813814_0001104659-25-103726_tm2529652d1_ex99-1.htm:5]** 
- The lead clinical program, **MM120 ODT**, is in ongoing Phase 3 studies for Generalized Anxiety Disorder (GAD) and Major Depressive Disorder (MDD).  **[1813814_0001104659-25-103726_tm2529652d1_ex99-1.htm:5]** 
- **Three Phase 3 topline readouts** for MM120 ODT are anticipated in **2026**: MM120-300 for GAD in **1H 2026**, MM120-301 for GAD in **2H 2026**, and MM120-310 for MDD in **Mid 2026**.  **[1813814_0001104659-25-103726_tm2529652d1_ex99-1.htm:8]**  
- MM120 ODT has been granted **Breakthrough Therapy Designation by the U.S. FDA**.  **[1813814_0001104659-25-103726_tm2529652d1_ex99-1.htm:9]**

Mind Medicine (MindMed) Inc. Reports Q3 2025 Cash Position and Upcoming Phase 3 Readouts

- **Mind Medicine (MindMed) Inc.** announced its intention to offer and sell **common shares and pre-funded warrants** in an underwritten public offering.  **[1813814_0b4d3969f9564108b5265f80baa57a79_0]** 
- The **net proceeds** from this offering are intended to fund **research and development** of its product candidates, working capital, and general corporate purposes, with a potential portion for investments or acquisitions.  **[1813814_0b4d3969f9564108b5265f80baa57a79_0]** 
- **Jefferies LLC, Leerink Partners, and Evercore ISI** are acting as joint bookrunning managers for the offering, which is **subject to market conditions** and has no assurance of completion or specific terms.  **[1813814_0b4d3969f9564108b5265f80baa57a79_0]**

MindMed Announces Proposed Public Offering

- MindMed's MM120 (LSD), a **serotonin 2A agonist**, is being developed for **Generalized Anxiety Disorder (GAD)**, an indication affecting an estimated **10% of the U.S. adult population (26 million people)**, where the last approval was in 2007.  **[1813814_2147414_0]** 
- The Phase 2b study of MM120 for GAD showed a **7.7 unit improvement** over placebo at 12 weeks with a single dose, which is more than double typical approved drugs, and achieved a **48% remission rate** and **65% response rate** at 12 weeks in the **100 microgram arm**.  **[1813814_2147414_4]** 
- Adverse events were primarily limited to the day of dosing, with the **100 microgram dose** resulting in a "remarkably benign" patient experience and a reduced monitoring time from 12 hours in Phase 2 to **8 hours** in Phase 3.  **[1813814_2147414_2]** **[1813814_2147414_3]** 
- MM120 has received **Breakthrough Therapy Designation** from the FDA, and MindMed is comfortable with its Phase 3 program design for both GAD and Major Depressive Disorder (MDD).  **[1813814_2147414_5]**

Mind Medicine (MindMed) Discusses MM120 Phase 2b GAD Data and Phase 3 Plans

Mind Medicine (MindMed) (MNMD)